Y-mAbs Therapeutics, Inc. (YMAB) Stock Analysis
DELISTED 2025
What happened to Y-mAbs Therapeutics, Inc. (YMAB) stock?
Y-mAbs Therapeutics, Inc. (YMAB) no longer trades on public markets. It was delisted in September 2025. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Y-mAbs Therapeutics, Inc. (YMAB) trades at $8.61. Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in antibody-based therapies for cancer treatment. Market cap: $391M, Sector: Healthcare.
Last analyzed: May 10, 2026Analyst Coverage for YMAB: YMAB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates YMAB against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
YMAB: 2/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Y-mAbs Therapeutics, Inc. (YMAB) Healthcare & Pipeline Overview
Y-mAbs Therapeutics, Inc. is a pioneering biopharmaceutical company dedicated to developing antibody-based therapies for cancer, with a focus on pediatric neuroblastoma and a robust clinical pipeline that positions it well in the competitive oncology landscape.
What Is the Investment Thesis for YMAB?
Y-mAbs Therapeutics, Inc. presents a compelling investment thesis driven by its innovative product pipeline and strategic partnerships. The company’s lead product, DANYELZA, has already gained traction in the market, addressing a critical need for pediatric neuroblastoma therapies. With a gross margin of 79.8%, Y-mAbs demonstrates strong potential for profitability as it scales its operations. The ongoing clinical trials for DANYELZA and other products, such as the GD2-GD3 vaccine and Omburtamab, are expected to yield results that could drive revenue growth and expand market share. The biopharmaceutical market for oncology is projected to grow significantly, and Y-mAbs is well-positioned to capitalize on this trend with its unique offerings. However, the company faces risks related to regulatory approvals and competition in the biotechnology sector, which could impact its growth trajectory.
Based on FMP financials and quantitative analysis
YMAB Key Highlights
Market Cap of $391M reflects strong investor interest in innovative cancer therapies.
- Gross Margin of 79.8% indicates high profitability potential as products gain market acceptance.
- Profit Margin of -22.7% highlights ongoing investment in R&D and clinical trials.
- Beta of 0.53 suggests lower volatility compared to the broader market, appealing to risk-averse investors.
- No dividend yield as the company reinvests earnings into product development and clinical trials.
Who Are YMAB's Competitors?
YMAB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NVS Novartis AG | $160.31 | +3.73% | $305B | 57 |
| BMY Bristol-Myers Squibb Company | $65.47 | -3.17% | $134B | 90 |
| AMGN Amgen Inc. | $442.36 | +4.02% | $239B | 86 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| MDXG MiMedx Group, Inc. | $4.45 | +2.53% | $649M | 90 |
| CRMD CorMedix Inc. | $8.33 | -2.19% | $654M | 95 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are YMAB's Key Strengths?
Innovative product pipeline focused on pediatric oncology.
- Strong gross margin indicating potential for profitability.
- Strategic partnerships with leading research institutions.
What Are YMAB's Weaknesses?
Negative profit margin reflecting ongoing R&D investments.
- Limited product portfolio focused primarily on niche markets.
- Dependence on successful clinical trial outcomes.
What Could Drive YMAB Stock Higher?
YMAB catalyst: Results from Phase II trials for DANYELZA in first-line and third-line neuroblastoma are expected in Q3 2026.
- Clinical trials for GD2-GD3 vaccine and Omburtamab are actively recruiting patients.
- Potential partnership announcements to enhance R&D capabilities are anticipated in 2026.
What Are the Key Risks for YMAB?
Negative return on equity (-9.5%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory approval delays for key products could hinder market entry.
- Competition from larger biopharmaceutical companies may impact market share.
- Clinical trial failures could result in significant financial losses.
What Are the Growth Opportunities for YMAB?
- Growth opportunity 1: The pediatric oncology market is projected to grow at a CAGR of 5.5% through 2026, driven by increasing awareness and advancements in treatment options. Y-mAbs' lead product, DANYELZA, targets a significant unmet need in relapsed or refractory high-risk neuroblastoma, positioning the company to capture a substantial share of this growing market.
- Growth opportunity 2: The GD2-GD3 vaccine, currently in Phase II trials, has the potential to address Stage 4 high-risk neuroblastoma, a critical area with limited treatment options. If successful, this product could significantly enhance Y-mAbs' portfolio and revenue streams, tapping into a market that is expected to expand as new therapies are developed.
- Growth opportunity 3: Y-mAbs is developing Omburtamab for central nervous system metastases, a niche yet impactful area in oncology. The increasing incidence of brain metastases in pediatric cancer patients presents a market opportunity that could be worth billions, especially if the drug receives expedited regulatory approval.
- Growth opportunity 4: The ongoing development of Nivatrotamab for small cell lung cancer targets a large adult patient population, expanding Y-mAbs' reach beyond pediatric oncology. The small cell lung cancer market is expected to grow significantly, providing a lucrative opportunity for the company to diversify its product offerings.
- Growth opportunity 5: Strategic partnerships with leading institutions like Memorial Sloan Kettering Cancer Center and MIT enhance Y-mAbs’ research capabilities and accelerate the development of innovative therapies. These collaborations could lead to breakthroughs in treatment and open new avenues for funding and market access.
What Threats Does YMAB Face?
- Intense competition from established biopharmaceutical companies.
- Regulatory hurdles that could delay product approvals.
- Market volatility impacting funding and investment.
What Are YMAB's Competitive Advantages?
- Strong intellectual property portfolio protecting innovative therapies.
- Exclusive partnerships with leading cancer research institutions.
- Focus on a niche market with significant unmet needs in pediatric oncology.
- Experienced leadership team with a track record in biopharmaceutical development.
What Does YMAB Do?
Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in Princeton, New Jersey. The company emerged from a vision to develop innovative antibody-based therapeutics for cancer treatment, particularly targeting pediatric patients suffering from aggressive forms of the disease. Its flagship product, DANYELZA, is a monoclonal antibody combined with granulocyte-macrophage colony-stimulating factor, specifically designed for treating relapsed or refractory high-risk neuroblastoma in children. Y-mAbs has made significant strides in its clinical pipeline, with DANYELZA also undergoing Phase II studies for first-line neuroblastoma, third-line neuroblastoma, and relapsed osteosarcoma. The company is advancing its GD2-GD3 vaccine, currently in Phase II trials, aimed at Stage 4 high-risk neuroblastoma, and Omburtamab, which targets central nervous system metastases from neuroblastoma and other tumors. Additionally, Y-mAbs is developing Nivatrotamab for small cell lung cancer and Lu-omburtamab-DTPA for medulloblastoma, both of which are in early clinical stages. The company's strategic partnerships, including a license agreement with the prestigious Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology, enhance its research capabilities and market reach. With a dedicated workforce of 104 employees, Y-mAbs is positioned to make a significant impact in the oncology market, focusing on unmet needs in pediatric cancer treatment.
What Products and Services Does YMAB Offer?
- Develop antibody-based therapeutics for cancer treatment.
- Focus on pediatric oncology, specifically neuroblastoma.
- Commercialize DANYELZA, a treatment for relapsed or refractory high-risk neuroblastoma.
- Conduct clinical trials for various cancer therapies, including vaccines and monoclonal antibodies.
- Collaborate with leading research institutions to enhance drug development.
- Aim to address unmet medical needs in oncology with innovative treatments.
How Does YMAB Make Money?
- Generate revenue through the commercialization of approved therapies.
- Engage in partnerships and collaborations for research and development.
- Leverage clinical trial results to attract investment and funding.
- Focus on niche markets within oncology to maximize impact and profitability.
What Industry Does YMAB Operate In?
The biotechnology industry, particularly in oncology, is experiencing rapid growth, driven by advancements in personalized medicine and immunotherapy. The global oncology therapeutics market is projected to reach $250 billion by 2026, with a significant focus on pediatric cancer treatments. Y-mAbs Therapeutics, Inc. operates within this dynamic landscape, competing with other biopharmaceutical companies that are developing innovative therapies. The company’s focus on antibody-based treatments for high-risk pediatric cancers positions it uniquely, as there is a critical need for effective therapies in this underserved market segment.
Who Are YMAB's Key Customers?
- Pediatric patients suffering from high-risk neuroblastoma.
- Oncology healthcare providers and hospitals.
- Research institutions and cancer treatment centers.
- Pharmaceutical partners for collaborative development.
How Y-mAbs Therapeutics, Inc. Is Valued
Y-mAbs Therapeutics, Inc. carries a market capitalization of $391M, placing it in the small-cap category.
Company Profile
Y-mAbs Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Princeton, US. The company is led by CEO Michael Rossi. YMAB has traded publicly since 2018.
Key Financial Metrics
Return on equity for Y-mAbs Therapeutics, Inc. stands at -9.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -7.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.00 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.2%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Y-mAbs Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.77 places it in the grey zone, a middle ground that warrants monitoring.
Forward Outlook
Wall Street analysts project Y-mAbs Therapeutics, Inc. revenue of about $95.3M for fiscal 2026, with EPS near $-0.88. The estimate reflects 6 contributing analysts.
YMAB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Y-mAbs has recently announced promising clinical trial results for its lead product, which has generated excitement among investors and the medical community.
- Insider buying has been observed, indicating that executives have confidence in the company's future prospects and growth potential.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative approach to cancer therapies.
- Recent partnerships and collaborations with major healthcare institutions have strengthened Y-mAbs' market position and credibility.
Bear Case
- Concerns about regulatory hurdles persist, as the approval process for new therapies can be unpredictable and lengthy, impacting investor sentiment.
- The biotech sector has faced increased scrutiny, leading to broader market volatility that can negatively affect Y-mAbs' stock performance.
- Some community members express skepticism over the sustainability of recent gains, fearing that enthusiasm may not translate into long-term success.
- Recent cash burn rates have raised alarms about the company's financial health, prompting fears about its ability to fund ongoing research and operations.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
YMAB Latest News
No recent news available for YMAB.
Leadership: Michael Rossi
CEO
Michael Rossi has a robust background in biopharmaceutical management, with over 15 years of experience in the industry. He holds a degree in Biology from Harvard University and an MBA from Stanford. Prior to joining Y-mAbs, he held leadership positions at several biotech firms, focusing on drug development and commercialization strategies.
Track Record: Under Michael's leadership, Y-mAbs has successfully launched DANYELZA and advanced multiple products through clinical trials. His strategic vision has positioned the company for growth in the competitive oncology market.
Y-mAbs Therapeutics, Inc. Healthcare Stock: Key Questions Answered
What happened to Y-mAbs Therapeutics, Inc. (YMAB) stock?
Y-mAbs Therapeutics, Inc. (YMAB) no longer trades on public markets. It was delisted in September 2025. The figures below are historical and are not a current quote.
Can I still buy YMAB shares?
No. YMAB stopped trading on public markets in September 2025, so the shares are not available through a broker. Anything you see quoted for YMAB elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before YMAB stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Y-mAbs Therapeutics, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Y-mAbs Therapeutics, Inc. do?
Y-mAbs Therapeutics, Inc. is a biopharmaceutical company focused on developing antibody-based therapies for cancer treatment, particularly in pediatric oncology. The company’s lead product, DANYELZA, targets relapsed or refractory high-risk neuroblastoma, while its pipeline includes several other innovative treatments for various cancers.
What is Y-mAbs Therapeutics, Inc.'s drug pipeline status?
Y-mAbs Therapeutics, Inc. has a robust pipeline with several products in various stages of clinical trials. DANYELZA is already commercialized, while other candidates like the GD2-GD3 vaccine and Omburtamab are in Phase II trials, with results expected in the near future.
What are the main risks for YMAB?
Y-mAbs faces several risks, including potential delays in regulatory approvals for its therapies, which could impede market access. Additionally, the competitive landscape in oncology is intense, with larger firms posing a threat to market share. Clinical trial failures also represent a significant risk that could affect the company's financial stability.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information and may be subject to change.